Results 281 to 290 of about 26,569 (299)

Disorders of Tetrahydrobiopterin Metabolism

1990
Tetrahydrobiopterin (BH4) is required as a cofactor in the hydroxylation of phenylalanine, tyrosine and tryptophan. Inborn errors of BH4 metabolism may occur in the synthetic pathway or in the re-cycling of BH4. Patients often present with hyperphenylalaninaemia in association with progressive neurological disease, which develops despite early ...
openaire   +2 more sources

Endothelial dysfunction, endothelial nitric oxide bioavailability, tetrahydrobiopterin, and 5-methyltetrahydrofolate in cardiovascular disease. Where are we with therapy?

Microvascular Research, 2018
Matthew F. Yuyun, L. Ng, G. Ng
semanticscholar   +1 more source

Why Tetrahydrobiopterin?

1995
B, Mayer, E R, Werner
openaire   +2 more sources

Tetrahydrobiopterin and Dopamine Release

Psychiatry and Clinical Neurosciences, 1991
Yasuyoshi Watanabe, Nobuko Mataga, Kazuyuki Imamura, Soichi Miwa, Per Hartvig, Joakim Tedroff, Hirotaka Onoe, Kunio Koshimura, Peter Bjurling, Bengt Långström   +9 more
openaire   +3 more sources

Tetrahydrobiopterin and endothelial function.

European heart journal, 1998
Tetrahydrobiopterin is an essential co-factor required for catalytic activity of nitric oxide synthases. A close link between tetrahydrobiopterin and nitric oxide synthesis has been recently demonstrated in a number of different cell types, including endothelial cells.
COSENTINO, Francesco, Lüscher TF
openaire   +2 more sources

Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson’s disease (PD): historical overview and future prospects

Journal of neural transmission, 2016
T. Nagatsu, I. Nagatsu
semanticscholar   +1 more source

Tetrahydrobiopterin and Mild Phenylketonuria

New England Journal of Medicine, 2003
Ponzone A, Peduto A, Spada M
openaire   +2 more sources

Tetrahydrobiopterin Therapy for Phenylketonuria

2015
Sapropterin dihydrochloride is a pharmaceutical preparation of BH4 available in 100 mg tablets or powder, which can be administered at doses of 5–20 mg/kg/day, for those individuals with BH4-responsive PKU. In clinical trials, 20–61 % of individuals with phenylketonuria (PKU) have been found to respond to tetrahydrobiopterin (BH4) as demonstrated ...
openaire   +2 more sources

TETRAHYDROBIOPTERIN METABOLISM IN DEPRESSION

The Lancet, 1984
A. Coppen, Gavin P. Reynolds, S.B. Whitburn, J.A. Blair, C. Morar, R.J. Leeming, Anne E. Pheasant, P.A. Barford, Christopher G.B. Hamon   +8 more
openaire   +3 more sources

Tetrahydrobiopterin for patients with phenylketonuria

The Lancet, 2007
Aurora Martinez, Angel L. Pey
openaire   +3 more sources